Creative Biolabs can directly provide customers with high-quality RNA-based tumor cell test services or products, and provide flexible customized solutions at an economical price to meet the diverse needs of scientific researchers. We have a professional project management team to provide you with comprehensive pre-sales consultation, order design, project progress updates, and after-sales service to ensure the smooth progress of each of your projects. Welcome inquiry!

Introduction to RNA Modification Tumor Cellular Metabolism Assay

In Creative Biolabs, we have developed a range of tumor cell metabolic analysis assays based on various RNA-modified types, including but not limited to, m6A, 5-methylcytosine (m5C), N1-methyladenosine, Pseudouridine, 7-methylguanosine, and m1A. Through the regulation of diverse RNA metabolic processes, we will continuously monitor changes in the tumor microenvironment level and offer comprehensive analysis services for tumor cell proliferation, differentiation, stress adaptation, invasion, and drug resistance mechanisms.

Furthermore, we have connected the reprogramming of transcriptomic mechanisms to diverse cancer models, offering precise transcriptomic biomarker detection services in specific cell types or tumor microenvironments while aiding in identifying potential carcinogenic or tumor suppressor effects from abnormal modifications. Our meticulous analysis assays based on surface transcriptome features are critical for pinpointing exact molecular targets and developing highly selective and effective immune-oncology research tools.

Distributed under Unsplash License, from Unsplash.

Services

Up to now, we have generated a series of assays to assist in the analysis of metabolic characteristics and pathways of cancer cells, enabling the detection of several metabolites involved in tumor cell processes. The detection system we have built can further facilitate a better understanding of the metabolic needs and defects of tumor and immune cells in TME, as well as provide crucial data support for the development of new and effective immunotherapies.

• Metabolite secretion assay
• Mitochondrial function assay
• Cell enzyme activity assay
• KEGG pathway enrichment analysis assay
• In vivo deficiency of ALKBH5 cytokines expression analysis assay
• Pathway and energy consumption analysis assay
• Glycogen standard curve measurement assay

Case study: m6A RNA methylation in cancer metabolism

In the past few years, Creative Biolabs has developed many RNA modification tumor cellular metabolism assays for rapid and quantitative detection of RNA modifications. We integrate second-generation sequencing techniques with indirect approaches such as antibody-based immunoprecipitation or chemical labeling, leveraging the unique base modification properties of RNA pairs to explore the biological functions of various RNA modifications in tumor cell metabolism.

Fig.1 RNA modification on disease metabolism.¹

In a recent project, we investigated the correlation between m6A RNA methylation and tumor cell reprogramming. By analyzing the role of m6A RNA methylation modification in various endogenous and exogenous signaling pathways of tumors, we have found that m6A methylase and its processes can be used as important regulatory factors in the metabolic reprogramming of tumor cells. Of particular importance, targeting m6A methylases and signaling pathways can also be the new direction for us to discover novel cancer immunotherapies.

Based on tumor genome and epigenome, Creative Biolabs can combine RNA modification research with various tumor pathogenesis analysis levels, such as immunity, inflammation, proliferation, metastasis, microenvironment, and energy metabolism reprogramming. We are determined to master the global process of tumor development and change and provide comprehensive new solutions for the study of its regulatory mechanism and new immunotherapies. If you are interested in our services, please feel free to contact us.

Reference

1. Liu, Wei-Wei, et al. "RNA modifications in cellular metabolism: implications for metabolism-targeted therapy and immunotherapy." Signal Transduction and Targeted Therapy 9.1 (2024): 70. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only | Not For Clinical Use